Cargando…

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys

The development of immunologic interventions that can target the viral reservoir in HIV-1-infected individuals is a major goal of the HIV-1 cure field(1,2). However, little evidence exists that the viral reservoir can be sufficiently targeted to improve virologic control following discontinuation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borducchi, Erica N., Cabral, Crystal, Stephenson, Kathryn E., Liu, Jinyan, Abbink, Peter, Ng’ang’a, David, Nkolola, Joseph P., Brinkman, Amanda L., Peter, Lauren, Lee, Benjamin C., Jimenez, Jessica, Jetton, David, Mondesir, Jade, Mojta, Shanell, Chandrashekar, Abishek, Molloy, Katherine, Alter, Galit, Gerold, Jeff M., Hill, Alison L., Lewis, Mark G., Pau, Maria G., Schuitemaker, Hanneke, Hesselgesser, Joseph, Geleziunas, Romas, Kim, Jerome H., Robb, Merlin L., Michael, Nelson L., Barouch, Dan H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5145754/ https://www.ncbi.nlm.nih.gov/pubmed/27841870 http://dx.doi.org/10.1038/nature20583

Ejemplares similares

Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation
por: Liu, Po-Ting, et al.
Publicado: (2020)

Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
por: Ventura, John D., et al.
Publicado: (2022)

Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2018)

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys
por: Moldt, Brian, et al.
Publicado: (2022)

Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques
por: Cadena, Anthony M., et al.
Publicado: (2021)

Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation
por: Bricker, Katherine M., et al.
Publicado: (2020)

Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys
por: Whitney, James B., et al.
Publicado: (2014)

Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques
por: Walker-Sperling, Victoria E. K., et al.
Publicado: (2022)

Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys
por: Keele, Brandon F., et al.
Publicado: (2017)

Development of a novel simian adenovirus 24 based vaccine vector
por: Abbink, P, et al.
Publicado: (2012)

A B cell follicle sanctuary permits persistent productive SIV infection in elite controllers
por: Fukazawa, Yoshinori, et al.
Publicado: (2015)

Evidence for Env-V2 sieve effect in breakthrough SIV (MAC251) infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs
por: Sina, S, et al.
Publicado: (2012)

Rapid Loss of CD4 T Cells by Pyroptosis during Acute SIV Infection in Rhesus Macaques
por: He, Xuan, et al.
Publicado: (2022)

Search for small molecule activators of latent HIV
por: Geleziunas, Romas, et al.
Publicado: (2012)

Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys
por: Boopathy, Archana V., et al.
Publicado: (2023)

Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV
por: Brown, Eric P., et al.
Publicado: (2018)

OA07-03. Influence of preexisting vaccinia immunity on a DNA/MVA SIV vaccine, decreased cellular immunity but enhanced control of a pathogenic SIV challenge
por: Kannanganat, S, et al.
Publicado: (2009)

Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice
por: Larocca, Rafael A., et al.
Publicado: (2021)

PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy
por: Bekerman, Elena, et al.
Publicado: (2019)

Selective SARS-CoV2 BA.2 escape of antibody Fc/Fc-receptor interactions
por: Bartsch, Yannic C., et al.
Publicado: (2023)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
por: Vidal, Samuel J., et al.
Publicado: (2021)

Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys
por: Barouch, Dan H., et al.
Publicado: (2012)

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections
por: Kwa, S, et al.
Publicado: (2012)

Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy
por: Whitney, James B., et al.
Publicado: (2018)

Vaccine Protection Against Zika Virus from Brazil
por: Larocca, Rafael A., et al.
Publicado: (2016)

Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies
por: Dugast, Anne-Sophie, et al.
Publicado: (2014)

Human Immunodeficiency Virus Type 1-Associated Cd4 Downmodulation
por: Geleziunas, Romas, et al.
Publicado: (1994)

Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys
por: Liu, Jinyan, et al.
Publicado: (2008)

Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C
por: Tartaglia, Lawrence J., et al.
Publicado: (2020)

GM-CSF co-expressing DNA/MVA vaccine, prevention of acquisition by two series of SIVE660 challenges followed by a series of SIV251 challenges
por: Robinson, H, et al.
Publicado: (2012)

Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization
por: Maxfield, Lori F., et al.
Publicado: (2015)

Significant protection from infection and AIDS progression after gastrointestinal and oral vaccinations, respectively, with a SIV DNA/rMVA vaccine
por: Aldovini, A, et al.
Publicado: (2012)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques
por: Nkolola, Joseph P., et al.
Publicado: (2022)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
por: Meseda, Clement A., et al.
Publicado: (2016)

The 90 MVA transformer
Publicado: (1974)

Models of SIV rebound after treatment interruption that involve multiple reactivation events
por: van Dorp, Christiaan H., et al.
Publicado: (2020)

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
por: Yu, Jingyou, et al.
Publicado: (2021)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_8dpjsro2hgblod9irsm25m8re2